Opioid Use Disorder and Withdrawal
Contents (10)
Opioid use disorder (OUD) is a chronic relapsing-remitting condition characterized by compulsive opioid use despite harmful consequences, defined by DSM-5 criteria requiring ≥2 of 11 behavioral/psychological symptoms over 12 months. The opioid epidemic has become a major public health crisis in North America, with over 100,000 opioid-related deaths annually in the United States, driven by prescription opioids, heroin, and increasingly potent synthetic opioids like fentanyl. OUD affects individuals across all socioeconomic strata, with peak incidence in young adults (18-25 years) but rising prevalence in older adults; approximately 2.7% of Americans have lifetime OUD. Opioid withdrawal, while rarely life-threatening, causes profound physiological and psychological distress that drives continued use and relapse, making recognition and evidence-based treatment essential for clinical practice and board examinations. Understanding both the neurobiology of dependence and the clinical management of acute withdrawal is critical for emergency medicine, psychiatry, and primary care physicians.
Key Mechanism 1: Opioid Receptor Signaling and Mu-Receptor Downregulation
Exogenous opioids bind to μ (mu) opioid receptors distributed throughout the central and peripheral nervous systems (highest concentration in nucleus accumbens, ventral tegmental area, dorsal root ganglia, and gastrointestinal tract). These G-protein coupled receptors activate inhibitory Gi/Go proteins, decreasing intracellular cyclic adenosine monophosphate (cAMP) and reducing neuronal excitability. This acute hyperpolarization produces analgesia, euphoria, respiratory depression, and miosis. With chronic exposure, the brain adapts through neuroadaptation: μ-receptor density decreases (downregulation), G-protein coupling efficiency diminishes, and compensatory upregulation of opposing excitatory systems occurs, including increased activity of the adenylyl cyclase pathway and enhanced glutamatergic/GABAergic balance. This fundamentally alters the baseline set point of neuronal function.
Key Mechanism 2: Upregulation of Excitatory Neurotransmitter Systems
During chronic opioid exposure, the brain compensates for μ-receptor-mediated inhibition by upregulating excitatory glutamate signaling and downregulating inhibitory GABA signaling in key reward and stress circuits. Specifically, there is increased expression of NMDA receptor subunits and enhanced glutamatergic tone in the nucleus accumbens and prefrontal cortex. Additionally, the hypothalamic-pituitary-adrenal (HPA) axis and locus coeruleus-noradrenergic system become hyperactive, with increased corticotropin-releasing factor (CRF) and enhanced norepinephrine synthesis and release. When opioid supply is abruptly removed, these unopposed excitatory systems are no longer counterbalanced, producing the characteristic hyperadrenergic withdrawal syndrome.
Key Mechanism 3: Alterations in Reward Processing and Dopamine Dysregulation
Opioids activate dopamine neurons in the ventral tegmental area through both direct μ-receptor stimulation and indirect disinhibition (via inhibition of GABAergic interneurons). Chronic use leads to dopamine receptor downregulation (particularly D2 receptors) and reduced reward sensitivity to natural reinforcers (food, sex, social interaction). This anhedonia and altered reward processing perpetuate compulsive seeking behavior and craving. The development of conditioned place preference occurs through associative learning, where environmental cues become linked to drug effects, engaging the amygdala, dorsolateral prefrontal cortex, and hippocampus to trigger cravings even during abstinence.
Key Mechanism 4: Molecular Basis of Opioid Tolerance
Tolerance develops through multiple mechanisms: (1) receptor desensitization via phosphorylation and β-arrestin binding that uncouples receptors from G-proteins; (2) loss of receptor density through internalization and degradation; (3) NMDA receptor activation in the dorsal striatum that opposes opioid effects; and (4) altered intracellular signaling with reduced phospholipase C and increased PKC activity. These changes occur at different rates for different opioid effects—tolerance develops rapidly to euphoria and respiratory depression but more slowly to constipation and miosis, explaining why respiratory depression can persist despite tolerance to other effects.
Key Mechanism 5: Opioid Withdrawal as a Withdrawal Hyperexcitability Syndrome
Upon opioid cessation, abrupt loss of μ-receptor signaling results in unopposed activity of previously suppressed excitatory systems. In the locus coeruleus, there is a dramatic surge in noradrenergic tone, producing sympathomimetic symptoms (tachycardia, hypertension, diaphoresis, anxiety). In the spinal cord, loss of opioid-mediated inhibition of sensory neurons produces hyperalgesia and muscle aching. Increased glutamatergic signaling in the anterior cingulate and amygdala produces dysphoria, emotional distress, and insomnia. The temporal course of withdrawal correlates with the elimination half-life of specific opioids: short-acting agents (heroin, oxycodone) peak at 24-48 hours; long-acting agents (methadone) peak at 72-96 hours or later.
Major Cause 1: Prescription Opioid Exposure
Prescription opioids (oxycodone, hydrocodone, morphine, fentanyl transdermal) represent the gateway to OUD in many patients. Risk escalates with higher doses (>100 mg morphine equivalent daily), longer duration of therapy, and concurrent benzodiazepine or sedative use. Patients with legitimate acute or chronic pain may transition from appropriate therapeutic use to problematic use characterized by dose escalation, doctor-shopping, or diversion. The "opioid crisis wave" was initiated by aggressive marketing of extended-release oxycodone in the 1990s with false reassurances about addiction liability. Current prescription patterns and opioid-prescribing guidelines acknowledge this risk and emphasize nonpharmacological and non-opioid pharmacological pain management.
Major Cause 2: Heroin and Illicit Synthetic Opioids
Heroin (diacetylmorphine) has high bioavailability via intravenous, intranasal, and smoking routes, producing rapid onset of effects and high addiction liability. The proliferation of fentanyl (50-100× more potent than morphine) and carfentanil in illicit drug supplies has dramatically increased overdose fatalities; contamination of heroin and counterfeit pills with fentanyl accounts for a large proportion of recent opioid deaths. Illicit opioid use confers additional risks including infections (bacterial endocarditis, abscess, osteomyelitis), blood-borne pathogen transmission (HIV, hepatitis C), and overdose death.
Major Cause 3: Individual Risk Factors
- Genetic predisposition: Twin and family studies demonstrate heritability of ~50-60% for opioid addiction; specific polymorphisms in μ-receptor (OPRM1) and catecholamine metabolism genes influence addiction risk
- Psychiatric comorbidity: Major depressive disorder, anxiety disorders, PTSD, and ADHD frequently co-occur; these conditions increase relapse risk and complicate treatment
- Early trauma and adverse childhood experiences: Childhood trauma, sexual abuse, and early substance exposure increase vulnerability
- Social determinants: Poverty, limited education, social isolation, and lack of social support networks increase risk
- Environmental factors: Peer influence, easy drug availability, and community prevalence of substance use disorder
Major Cause 4: Pain and Medical Conditions
Chronic pain conditions (back pain, fibromyalgia, arthritis) commonly necessitate opioid therapy and increase risk of escalation to OUD. Patients with pain and comorbid psychiatric illness face particularly high risk. Cancer patients receiving opioids rarely develop OUD, suggesting that pain context and disease severity modulate addiction risk.
Cardinal Symptom 1: Craving and Compulsive Use
Craving—the intense desire to use opioids—represents a core symptom of OUD and may be triggered by environmental cues, emotional states, or periodic sensations of low-level withdrawal. Patients exhibit compulsive drug-seeking behavior, continued use despite knowledge of harmful consequences, and escalating use patterns to achieve the same effect (tolerance). This reflects the underlying neurobiology of altered reward sensitivity and conditioned responses mediated by amygdala, insula, and ventromedial prefrontal cortex.
Cardinal Symptom 2: Loss of Control and Failed Reduction Attempts
Patients report difficulty controlling use or reducing amounts, spending excessive time obtaining drugs, and abandoning social/occupational activities to pursue opioid use. This behavioral pattern reflects dysfunction in prefrontal cortex circuits governing executive function, impulse control, and decision-making.
Symptom 3: Tolerance and Escalating Doses
Patients require progressively higher doses to achieve the same analgesic or euphoric effects, reflecting μ-receptor downregulation and neuroadaptation. Tolerance develops at different rates for different effects—respiratory depression typically persists even when tolerance to euphoria is marked, a critical safety consideration in treatment.
Symptom 4: Continued Use Despite Harm
Persistent use despite physical health consequences (infections, hepatitis, overdose history), psychological consequences (depression, anxiety worsening), or social consequences (job loss, legal problems, relationship deterioration) is diagnostic of OUD.
Immediate stabilisation (suspected overdose)
- Airway and ventilation first: death in opioid overdose is from hypoventilation and hypercapnic respiratory failure, not the drug itself. Bag-mask ventilation precedes everything else.
- Opioid antagonist: naloxone, a competitive μ-receptor antagonist, given 0.4 mg IV/IM (or 4 mg intranasal in community naloxone kits) and repeated/titrated to adequate respiratory rate rather than to full arousal — in a dependent patient, over-antagonism precipitates florid withdrawal. Because naloxone's duration is shorter than that of most opioids (and far shorter than methadone or extended-release formulations), the patient must be observed for re-sedation; a naloxone infusion may be required. The CDC and SAMHSA recommend take-home naloxone for anyone with OUD or on high-dose opioid therapy.
First-line therapy — medications for opioid use disorder (MOUD): the ASAM National Practice Guideline for the Treatment of Opioid Use Disorder recommends pharmacotherapy as the standard of care; medication, not counselling alone, is what reduces mortality.
- Partial μ-agonist: buprenorphine (usually co-formulated with naloxone to deter injection). High receptor affinity plus a ceiling on respiratory depression makes it comparatively safe. It must be started only once objective withdrawal is present (a COWS score in the moderate range) or it will displace full agonists and precipitate withdrawal; low-dose ("micro-dose") initiation overlapping with the full agonist is increasingly used for fentanyl-exposed patients. Office-based prescribing no longer requires a DEA X-waiver following the 2023 federal change.
- Full μ-agonist: methadone, which for OUD maintenance may only be dispensed through a federally certified opioid treatment program (inpatients admitted for another condition may receive it for withdrawal).
Second-line / alternative
- Opioid antagonist: extended-release intramuscular naltrexone, appropriate for motivated abstinent patients; requires an opioid-free interval of roughly one to two weeks or it precipitates severe withdrawal.
- Alpha-2 agonists: lofexidine (FDA-approved) or clonidine blunt locus coeruleus noradrenergic surge but treat symptoms only — they are adjuncts, never a substitute for MOUD.
Contraindicated / avoid
- Withdrawal management alone ("detox") without ongoing MOUD: loss of tolerance sharply raises overdose death risk on relapse.
- Discontinuing MOUD in pregnancy: ACOG recommends buprenorphine or methadone maintenance; medically supervised withdrawal risks fetal distress and relapse.
- Reflexively withholding buprenorphine because of benzodiazepine or alcohol use — the FDA advises against this.
Emergencies
- Opioid overdose with respiratory depression: μ-receptor suppression of medullary chemoreceptor response to CO₂. Signalled by the triad of pinpoint pupils, depressed consciousness, and bradypnea; hypercapnia and hypoxemia follow. Fentanyl analogues may additionally cause chest wall rigidity ("wooden chest"), making bag-mask ventilation fail despite naloxone.
- Noncardiogenic pulmonary edema: frothy sputum and hypoxemia after overdose or abrupt naloxone reversal; diffuse infiltrates with a normal heart size.
- Infective endocarditis in people who inject drugs: classically right-sided tricuspid disease with Staphylococcus aureus; signalled by fever, septic pulmonary emboli on chest imaging, and a new murmur. Spinal epidural abscess (fever, back pain, focal neurologic deficit) and osteomyelitis are the other injection-related emergencies.
- Torsades de pointes from methadone: hERG potassium channel blockade prolongs the QTc; syncope or polymorphic VT in a patient on high-dose methadone, especially with hypokalemia or other QT-prolonging drugs. Baseline and follow-up ECG is standard.
- Neonatal opioid withdrawal: seizures and feeding failure in the exposed newborn — unlike adult withdrawal, this is potentially life-threatening.
Non-emergent but high-yield
- Precipitated withdrawal: buprenorphine or naltrexone displacing a full agonist produces abrupt, severe withdrawal within minutes to an hour of dosing — the timing relative to the dose is the clue.
- Loss of tolerance after abstinence: incarceration, inpatient detoxification, or antagonist therapy downregulates the adaptations described above; the previously tolerated dose then becomes lethal. This is the mechanism behind post-release overdose deaths.
- Blood-borne and skin infections: HCV, HIV, cellulitis, and wound botulism/tetanus from nonsterile injection.
- Rhabdomyolysis and compartment syndrome: prolonged immobility while obtunded; dark urine with markedly elevated creatine kinase and acute kidney injury.
- Opioid-induced constipation and hyperalgesia, plus hypogonadism: tolerance to constipation and miosis develops slowly, so these persist; hyperalgesia paradoxically worsens with dose escalation.
- Withdrawal-related volume depletion: vomiting and diarrhea causing hypovolemia and electrolyte loss, particularly dangerous in pregnancy, where withdrawal may precipitate preterm labor.
- The overdose triad is miosis, respiratory depression, and CNS depression: bradypnea, not pupil size, is what kills. Best next step is ventilation plus titrated naloxone — and because naloxone outlasts almost nothing, the stem's "patient re-sedates in the ED" is testing for redosing or an infusion.
- Mydriasis means withdrawal, miosis means intoxication: this single pupil finding separates the two stems. Add lacrimation, rhinorrhea, piloerection, yawning, and diarrhea — the classic "cold turkey" picture.
- Buprenorphine can precipitate withdrawal; wait for objective withdrawal before the first dose: high μ affinity but partial agonism displaces the full agonist. A patient who feels dramatically worse within an hour of the first sublingual dose has precipitated withdrawal, not "a bad reaction to naloxone in the film."
- The one association examiners love: methadone prolongs the QT interval: order an ECG before and during therapy, and think torsades if syncope appears.
- Extended-release naltrexone requires the patient to be fully opioid-free first: giving it too early precipitates withdrawal, and the antagonist-induced loss of tolerance makes relapse overdose more lethal.
- In pregnancy, maintain — do not withdraw: ACOG endorses buprenorphine or methadone; supervised withdrawal risks relapse and fetal compromise. Neonatal withdrawal is expected, treated with supportive Eat-Sleep-Console care and opioid if needed, and is not a reason to avoid MOUD or to discourage breastfeeding.
- Common distractor — clonidine as the answer: alpha-2 agonists (clonidine, lofexidine) relieve the noradrenergic symptoms but do not treat the disorder. When the question asks for the intervention that reduces mortality or relapse, choose buprenorphine or methadone (ASAM guideline).
- Second common distractor — "inpatient detoxification alone": detoxification without ongoing MOUD increases overdose death after discharge. Also remember every patient and household should leave with naloxone, per CDC/SAMHSA.
Early Signs (6-12 hours for short-acting; 24-48 hours for long-acting)
- Craving and anxiety: Intense desire for drug; generalized anxiety and irritability
- Autonomic hyperactivity: Lacrimation (tearing), rhinorrhea (nasal secretion), sweating, piloerection ("goosebumps")
- Gastrointestinal: Nausea, cramping, diarrhea (mediated by loss of opioid-induced suppression of acetylcholine)
- Sleep disturbance: Insomnia, vivid nightmares (from loss of opioid-mediated sleep promotion)
Peak Withdrawal Symptoms (24-48 hours for heroin; 72-96+ hours for methadone)
- Musculoskeletal pain: Severe myalgias, arthralgias, and muscle spasms (from spinal cord disinhibition)
- Cardiovascular: Tachycardia, hypertension, palpitations (from locus coeruleus hyperactivity)
- Dilated pupils (mydriasis): Characteristic finding from unopposed sympathomimetic tone
- Vomiting and diarrhea: Profound fluid loss from GI hyperactivity
- Restlessness and dysphoria: Inability to sit still, severe depressed mood
- Hyperalgia: Pain amplification from acute inflammatory state
Important Clinical Variants
- Neonatal abstinence syndrome (NAS): Infants born to opioid-dependent mothers exhibit withdrawal 48-96 hours after birth, manifesting as high-pitched cry, tremor, poor feeding, seizures, and hyperreflexia; requires supportive care and sometimes morphine/methadone taper
- Protracted withdrawal: Milder symptoms (anhedonia, insomnia, anxiety, fatigue) persist for weeks to months after acute withdrawal resolution; drives relapse vulnerability
- Acute-on-chronic presentation: Long-term opioid-dependent patients present with acute withdrawal after missed doses or incarceration
Physical Exam Findings
- Mydilasis (dilated pupils; classic sign)
- Piloerection ("goosebumps")
- Diaphoresis and tachycardia
- Tremor and muscle rigidity
- Hyperreflexia
- Restlessness and agitation
- Lacrimation and rhinorrhea
Diagnostic Approach: Clinical vs. Laboratory-Based
Diagnosis of opioid use disorder relies primarily on clinical history and DSM-5 criteria rather than laboratory testing, as urinary drug screens cannot differentiate therapeutic use from problematic use. However, objective testing supports the diagnosis and screens for complications.
DSM-5 Diagnostic Criteria for Opioid Use Disorder
A problematic pattern of opioid use requiring ≥2 of the following within 12 months:
- Opioids taken in larger amounts/longer period than intended
- Persistent desire or failed reduction attempts
- Excessive time obtaining/using opioids
- Craving or strong desire
- Recurrent failure to fulfill obligations (work, school, home)
- Continued use despite social/interpersonal problems
- Important activities abandoned/reduced
- Recurrent use in physically hazardous situations
- Continued use despite physical/psychological harm
- Tolerance (markedly increased amounts needed)
- Withdrawal symptoms when reduced/discontinued
Severity classification: Mild (2-3 symptoms), Moderate (4-5 symptoms), Severe (≥6 symptoms)
Historical Assessment
- Detailed substance use history: age of first use, progression to daily use, previous withdrawal episodes
- Route of administration (oral, intranasal, intravenous)—IV use confers higher addiction liability and complications
- Current opioid source (prescription vs. illicit) and estimated daily dose
- Previous treatment attempts and response
- Psychiatric history and suicide risk
- Medical history including chronic pain, hepatitis C status, HIV status, endocarditis risk
Objective Testing
Urine Drug Screen (UDS): Qualitative immunoassay detects opioid metabolites with variable sensitivity (85-95% depending on assay). Limitations: cannot quantify use, cannot differentiate prescribed from illicit opioids, variable detection windows (morphine/codeine: 24-48 hours; methadone: 72+ hours; fentanyl: 12-24 hours). Confirmatory gas chromatography-mass spectrometry (GC-MS) improves specificity (>99%) but is expensive.
Clinical Opiate Withdrawal Scale (COWS): Validated 11-item scale assessing resting pupil size, bone/joint aches, GI symptoms, tremor, sweating, anxiety, gooseflesh skin, nose running/tearing, GI tracks, and irritability. Score >5-12 indicates mild withdrawal; >12-24 indicates moderate; >24-36 indicates moderately severe; >36 indicates severe withdrawal. Sensitivity ~90%, useful for titrating medication doses.
Objective Opioid Withdrawal Scale (OOWS): 13-item scale measuring heart rate, systolic BP, tremor, GI symptoms, sweating, and pupil size. More objective than COWS but requires monitoring equipment.
Imaging and Ancillary Testing
- Chest X-ray: Screen for aspiration pneumonia, pulmonary edema (in acute overdose context) in IV opioid users with respiratory symptoms
- Electrocardiogram: Assess for QT prolongation in patients considering methadone (which can prolong QTc)
- Hepatitis C antibody and viral load: ~70% of IV opioid users have HCV; check baseline
- HIV testing: Recommended in all PWID; assess CD4 count if positive
- Liver function tests: Baseline assessment for HCV/HBV co-infection
- Comprehensive metabolic panel: Baseline renal function, electrolytes
Differential Diagnosis of Opioid Withdrawal
Must exclude:
- Alcohol withdrawal: CNS hyperexcitability but includes tremor, seizures, hallucinations; tachycardia and hypertension prominent
- Benzodiazepine withdrawal: Similar hyperexcitability but includes seizure risk, delirium, severe autonomic instability
- Thyroid storm: Severe tachycardia, hypertension, hyperthermia, agitation (check TSH)
- Sepsis: Fever, hypotension, organ dysfunction (key differentiator)
- Anticholinergic toxidrome: "Hot as a hare, dry as a bone" (dry skin, mydriasis) vs. withdrawal's diaphoresis
- Stimulant intoxication (cocaine, methamphetamine): Presents with sympathomimetic symptoms but pupils typically dilated from sympathomimetic effect rather than withdrawal
- Other substance withdrawal or medical illness: Comprehensive history and physical examination essential
First-Line Treatment 1: Methadone Maintenance and Induction
Mechanism: Full μ-opioid agonist with long half-life (24-48 hours), preventing withdrawal and reducing craving; produces